Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports
Lantheus Holdings is reportedly considering a sale following a $7 billion takeover offer from private-equity-backed Curium Pharma. The two radiopharmaceutical companies have been in discussions, with a potential deal possibly weeks away, though no final decision has been made. Lantheus's shares were down nearly 2% in extended trading but have gained significantly this year.
Lantheus Holdings gains after report it's evaluating a sale after offer
Lantheus Holdings stock gained after a report stated the company is evaluating a potential sale following an acquisition offer. The company, known for its diagnostic imaging agents, has reportedly received interest from multiple parties.
Lantheus weighs potential $7 billion sale following offer from Curium - Bloomberg news
Lantheus Holdings Inc. is reportedly considering a potential sale for approximately $7 billion after receiving an offer from Curium. This news, originally reported by Bloomberg, suggests a significant development for the radiopharmaceutical company. Lantheus (LNTH) is exploring its options following the acquisition proposal.
Lantheus Holdings stock hits 52-week high at 101.01 USD
Lantheus Holdings Inc. stock reached a new 52-week high of $101.01, demonstrating strong performance with a 27.74% appreciation over the past year and a 69% surge in the last six months. This milestone is supported by positive analyst revisions and a "GREAT" financial health rating from InvestingPro, as well as impressive Q1 2026 financial results that surpassed analyst expectations in both adjusted earnings per share and revenue.
Lantheus Weighs Potential $7 Billion Sale Following Offer From Curium
Lantheus Holdings Inc. is reportedly considering a sale after receiving a takeover offer from Curium, valuing the radiopharma company at approximately $7 billion. Discussions between the two companies are ongoing, and a deal could be finalized within weeks, though there is no guarantee of an agreement.
Lantheus Holdings stock (US5156731020): Q1 beat keeps guidance on track
Lantheus Holdings (LANT) delivered stronger-than-expected Q1 2026 results, beating analyst estimates with quarterly sales of $377.3 million and net income of $118.4 million. The company reaffirmed its full-year 2026 revenue guidance of $1.40 billion to $1.45 billion, boosted by its radiopharmaceutical portfolio and upcoming presentations at ASCO 2026 focusing on new oncology treatments and real-world prostate cancer imaging data. Despite a measured short interest, the company is strategically positioned at the intersection of oncology, cardiology, and advanced imaging technology, emphasizing its role in precision medicine.
Should Lantheus’ Q1 Beat And ASCO 2026 Pipeline Update Require Action From Lantheus Holdings (LNTH) Investors?
Lantheus Holdings reported strong Q1 2026 results and reaffirmed its full-year revenue guidance, with upcoming ASCO 2026 presentations on its investigational therapy LNTH-2403 and prostate cancer imaging data. These developments, along with the recent FDA approval of PYLARIFY TruVu, suggest the company is evolving into a broader radiopharmaceutical platform. However, investors should remain aware of potential pricing pressure in PSMA PET imaging and reimbursement shifts that could impact its future performance.
Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology ...
Lantheus Holdings, Inc. announced that data will be featured at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will include details on a Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, and anti-neoplastic activity of 177Lu-labeled monoclonal antibody in patients with relapsed/refractory osteosarcoma, and real-world use of piflufolastat F 18 in early-stage prostate cancer. Lantheus is a radiopharmaceutical-focused company aiming to improve patient outcomes.
Cancer trial data on LNTH-2403 and prostate imaging headed to ASCO 2026
Lantheus (NASDAQ: LNTH) announced it will present new radiopharmaceutical data at the 2026 ASCO Annual Meeting, held May 29–June 2, 2026. The presentations will include a Phase 1/2 study of LNTH-2403 in relapsed/refractory osteosarcoma and a publication-only abstract on the real-world use of piflufolastat F 18 in early-stage prostate cancer. This announcement follows recent positive news for Lantheus, including strong Q1 2026 earnings and FDA approvals for PYLARIFY TruVu and tentative approval for PNT2003.
Lantheus Holdings (LNTH) grants director 4,137 common shares
Lantheus Holdings (LNTH) director Minnie Baylor-Henry was granted 4,137 shares of common stock as a compensation-related award with a stated price of $0.00 per share. Following this transaction, Baylor-Henry directly holds 14,018 shares, with an additional 16 shares held indirectly through her spouse's IRA. The filing indicates this was an acquisition and not a market purchase, with no share sales reported.
Lantheus (LNTH) director granted 4,137 common shares
Lantheus Holdings, Inc. director Gerard Ber was granted 4,137 shares of common stock on May 14, 2026, as a compensation-related award with a price of $0.00 per share. Following this grant, Ber directly holds 27,499 shares of Lantheus common stock. This transaction was reported in a Form 4 SEC filing, detailing the non-derivative acquisition.
Director at Lantheus (NASDAQ: LNTH) receives 4,137-share stock grant
Lantheus Holdings director Sam R. Leno has received a grant of 4,137 shares of common stock at a price of $0.00 per share, which is a compensation-related award rather than an open-market trade. This transaction increased his direct holdings in the company to 67,246 common shares. The details of this insider trading activity were reported in a Form 4 filing, categorized as a "Grant, award, or other acquisition," signifying an equity award.
Lantheus (NASDAQ: LNTH) director Gary J. Pruden awarded 4,137 shares
Lantheus Holdings director Gary J. Pruden was awarded 4,137 shares of common stock at a price of $0.00 per share, as detailed in a recent Form 4 SEC filing. This grant increases his direct holdings to 6,674 shares, with additional indirect holdings through two revocable trusts. The transaction is classified as an equity compensation grant rather than an open-market purchase, and it has a neutral impact and sentiment rating.
Lantheus Holdings (LNTH) price target increased by 10.39% to 103.33
This article reports that the price target for Lantheus Holdings (LNTH) has been increased by 10.39%, raising it to $103.33. No further details are provided regarding the reasons for this adjustment or the analyst responsible.
Lantheus Holdings Inc stock (US5156731020): analysts see upside after recent volatility
Lantheus Holdings Inc (LNTH) shares have experienced volatility, yet Wall Street analysts maintain a positive outlook, projecting mid-single-digit upside over the next 12 months with a consensus price target around $99.71 USD. The company, a specialist in diagnostic imaging and theranostics, is driven by its PYLARIFY product for prostate cancer and strategic expansion into Alzheimer's diagnostics. Despite market risks like pricing pressure and competition, analysts rate the stock with a "moderate buy," recognizing its strong position in key healthcare trends.
Lantheus Holdings Inc stock (US5156731020): Q1 2026 earnings beat and renewed interest in radiopharmaceuticals
Lantheus Holdings Inc reported stronger-than-expected Q1 2026 earnings, with EPS of $1.46 against estimates of $1.26, driven by its radiopharmaceutical portfolio, especially in oncology. This performance led to a positive market reaction and renewed investor confidence, although the company acknowledges risks related to reimbursement, competition, and operational complexities. The article highlights Lantheus's core business model in diagnostic imaging and radiopharmaceuticals for oncology and cardiology, its profitability metrics, and its relevance to US investors seeking exposure to precision diagnostics amidst healthcare themes.
Lantheus Holdings (LNTH) price target increased by 10.39% to 103.33
This article reports a significant increase in the price target for Lantheus Holdings (LNTH). The target has been raised by 10.39% to $103.33.
We Think You Should Be Aware Of Some Concerning Factors In Lantheus Holdings' (NASDAQ:LNTH) Earnings
Despite a market response that pushed up Lantheus Holdings' stock price after its earnings report, Simply Wall St advises caution due to worrying underlying factors. A significant portion of the reported profit was attributed to an "unusual item" of US$84 million, which may not be repeatable and could provide an overly positive impression of the company's true profitability. While earnings per share did increase by 14% last year, investors should look beyond this singular aspect to understand the company's full financial picture.
Lantheus Holdings stock (US5156731020): Q1 earnings beat sparks 44% YTD rally
Lantheus Holdings reported strong Q1 2026 earnings, with EPS of $1.46 beating estimates and revenue climbing to $377.3 million. This performance has fueled a 44.6% year-to-date rally in its stock, which hit new 52-week highs. The company's success is largely driven by its radiopharmaceutical products, particularly PYLARIFY for prostate cancer detection, and its leading position in the growing diagnostic imaging sector.
We Think You Should Be Aware Of Some Concerning Factors In Lantheus Holdings' (NASDAQ:LNTH) Earnings
Lantheus Holdings' recent earnings report, while seemingly solid, is influenced by an unusual US$84m gain, making its statutory profit appear stronger than its underlying profitability. Investors are cautioned that such unusual items are often not repeated, potentially giving an overly positive impression of the company's financial health. Despite a 14% increase in earnings per share, the article suggests deeper analysis beyond statutory profits is necessary due to this one-off gain.
Discipline and Rules-Based Execution in LNTH Response
This article provides an AI-generated analysis of Lantheus Holdings Inc. (NASDAQ: LNTH), noting strong near and mid-term sentiment, but elevated downside risk in the long term. It outlines three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and details multi-timeframe signal analysis for support and resistance. The report aims to offer disciplined, rules-based execution for various risk profiles.
If EPS Growth Is Important To You, Lantheus Holdings (NASDAQ:LNTH) Presents An Opportunity
Lantheus Holdings (NASDAQ:LNTH) has demonstrated significant earnings per share (EPS) growth of 30% per year over the last three years, driven by a 49% annual revenue increase. While past performance is strong, the stock has seen a 16% decline this year and the P/E ratio is above the industry average, suggesting it might be overvalued. However, analysts predict continued strong growth, making it a potentially attractive investment for those prioritizing EPS expansion.
Assessing Lantheus Holdings (LNTH) Valuation After Recent Share Price Momentum
Lantheus Holdings (LNTH) has shown strong share price performance recently, with significant returns over the past week, month, and three months, and a double-digit 1-year total return. Despite this momentum, the company's stock, currently at US$91.00, is considered modestly undervalued by analysts, who project a fair value of around US$93.92. This valuation is largely based on the anticipated success of their new high-yield PYLARIFY formulation, expected to improve margins and revenue growth in prostate cancer imaging.
Lantheus Holdings, Inc. (NASDAQ:LNTH) Q1 2026 Earnings Call Transcript
Lantheus Holdings, Inc. reported strong Q1 2026 results, beating earnings expectations with an EPS of $1.46. The company highlighted solid performance across its key products PYLARIFY, NEURACEQ, and DEFINITY, and discussed strategic advancements including the FDA approval of PYLARIFY TRUVU and tentative approval of PNT2003. Lantheus reiterated its full-year 2026 guidance, focusing on commercial execution, regulatory milestones, and preparing for future growth acceleration in 2027.
Lantheus (LNTH) Is Up 7.5% After PET-Focused Q1 Beat And New FDA Nod For PYLARIFY TruVu
Lantheus Holdings reported strong Q1 2026 results with increased revenue and net income, alongside FDA approvals for PYLARIFY TruVu and tentative approval for PNT2003. These developments, coupled with a SPECT business sale, reinforce the company's strategic shift towards PET-based oncology and neuroendocrine products. The PYLARIFY TruVu approval is particularly significant for improving the economic viability and reach of its PSMA PET business.
Lantheus Holdings (LNTH) One Off Gain Lifts Margins And Tests Earnings Quality Narratives
Lantheus Holdings (LNTH) reported Q1 2026 revenues of US$377.3 million and EPS of US$1.83, with net income of US$118.4 million, which included an US$84.1 million one-off gain. This gain, while boosting current margins, raises questions about the sustainability of profitability and the underlying earnings power, especially as forecast revenue and earnings growth are below broader US market expectations. Investors are prompted to examine the quality of these earnings in light of a 13.3% earnings growth forecast and a significant one-off event.
These Analysts Raise Their Forecasts On Lantheus After Upbeat Q1 Results
Lantheus Holdings (NASDAQ: LNTH) reported better-than-expected Q1 earnings, with EPS of $1.46 and sales of $377.330 million, surpassing analyst estimates. Following the strong performance, analysts from Mizuho and Citizens raised their price targets for the stock. Lantheus shares rose 3.1% on the news, reaffirming its FY2026 guidance.
LNTH: Lantheus Reports 1Q:26 Financial and Operational Results
Lantheus Holdings, Inc. (NASDAQ: LNTH) reported its Q1 2026 financial and operational results, achieving $377 million in revenue, a 1% increase year-over-year, with adjusted EPS of $1.46, down 5%. The company maintained its full-year 2026 guidance and highlighted strategic shifts towards PET radiodiagnostics, regulatory successes with Pylarify TruVu and tentative approval for PNT2003, and a strong cash position bolstered by the SPECT business divestiture. These developments are expected to position Lantheus for accelerated growth in 2027.
Lantheus Holdings stock hits 52-week high at 90.5 USD By Investing.com
Lantheus Holdings stock has reached a new 52-week high of 90.13 USD, reflecting a 7.1% increase over the past year and a 69% surge in the last six months. The company, known for its medical imaging and therapeutic products, is considered slightly undervalued according to InvestingPro analysis, despite recent developments like the FDA extending the review period for its drug candidate LNTH-2501 (Octevy) to June 29, 2026. Analysts from Citizens, William Blair, and Jefferies have maintained or raised their ratings and price targets, citing positive market projections and potential royalty opportunities.
Lantheus Holdings (LNTH) One Off Gain Lifts Margins And Tests Earnings Quality Narratives
Lantheus Holdings reported Q1 2026 revenue of US$377.3 million and basic EPS of US$1.83, with net income of US$118.4 million. The company's net margin improved to 18%, partly due to an US$84.1 million one-off gain, which raises questions about the sustainability of current profitability. While bulls point to historical growth, bears focus on slower projected growth and product concentration.
Lantheus Holdings, Inc. 1Q 2026: Revenue $377.3M, EPS $1.8— 10-Q Summary
Lantheus Holdings, Inc. reported strong first-quarter 2026 results, with revenue reaching $377.3 million and net income significantly increasing to $118.4 million compared to the prior year. The company saw diluted EPS rise to $1.80, driven by the continued performance of PYLARIFY and strategic acquisitions, alongside key FDA approvals and pipeline advancements.
Lantheus Holdings stock hits 52-week high at 90.5 USD
Lantheus Holdings (LNTH) stock recently reached a new 52-week high at $90.13, marking a 69% surge over the past six months and a 7.1% increase over the past year. Despite this growth, an InvestingPro analysis suggests the stock is slightly undervalued, boasting a "GREAT" financial health score. Recent news includes a three-month extension for the FDA review of its drug candidate LNTH-2501 (Octevy), with analysts maintaining positive ratings and Jefferies raising its price target to $110 due to strong projections for the PSMA PET market.
Earnings call transcript: Lantheus Holdings Q1 2026 beats forecasts, stock rises
Lantheus Holdings (LNTH) reported strong financial results for Q1 2026, exceeding both EPS and revenue forecasts, which led to a nearly 6% rise in its stock during pre-market trading. The company's performance was driven by key products like PYLARIFY and DEFINITY, strategic partnerships, and advancements in its pipeline, including the FDA approval of PYLARIFY TruVu. Lantheus reiterated its full-year 2026 guidance, expecting continued growth acceleration into 2027, despite competitive pressures and a pending CEO change.
Earnings Flash (LNTH) Lantheus Holdings, Inc. Reports Q1 Revenue $377.3M, vs. FactSet Est of $354.5M
Lantheus Holdings, Inc. (LNTH) reported Q1 revenue of $377.3 million, surpassing FactSet's estimate of $354.5 million. The company's adjusted earnings for Q1 fell, while revenue rose, and it maintained its 2026 guidance. This news led to an increase in shares pre-bell.
Lantheus (NASDAQ: LNTH) posts Q1 2026 results and secures FDA wins
Lantheus Holdings reported Q1 2026 revenue of $377.3 million, a 1.2% increase year-over-year, significantly boosted by a $59.3 million gain from the sale of its SPECT business, which led to a GAAP diluted EPS of $1.80. The company also secured several FDA milestones, including approval for a new PYLARIFY formulation and tentative approval for PNT2003, while reaffirming its full-year 2026 revenue and adjusted EPS guidance despite a decline in PYLARIFY sales and softer core profitability. These regulatory achievements and strong cash generation are seen as offsetting near-term challenges.
Lantheus Holdings: Q1 Earnings Snapshot
Lantheus Holdings Inc. reported strong first-quarter results, with profits reaching $118.4 million, or $1.80 per share. Adjusted earnings of $1.46 per share surpassed analyst expectations of $1.25 per share. The diagnostic imaging company also exceeded revenue forecasts, posting $377.3 million against an expected $358.1 million.
Earnings Flash (LNTH) Lantheus Holdings, Inc. Posts Q1 Adjusted EPS $1.46 per Share, vs. FactSet Est of $1.23
Lantheus Holdings, Inc. announced its Q1 adjusted EPS of $1.46 per share, significantly surpassing the FactSet estimate of $1.23. The company also reported Q1 revenue of $377.3 million, exceeding the FactSet estimate of $354.5 million, and maintained its 2026 guidance. Despite lower adjusted earnings for the quarter, the robust revenue growth led to a pre-bell rise in share prices.
Lantheus Holdings: Q1 Earnings Snapshot
Lantheus Holdings Inc. reported strong first-quarter results, with profits reaching $118.4 million, or $1.80 per share. Adjusted earnings of $1.46 per share surpassed Wall Street's expectations of $1.25 per share. The diagnostic imaging company also exceeded revenue forecasts, posting $377.3 million against an expected $358.1 million.
Lantheus in the spotlight: Can pipeline offset pricing headwinds?
Lantheus Holdings Inc. is set to report Q1 earnings, with investors focused on whether its new product pipeline can counter pricing pressures and increased competition for its key PSMA PET imaging franchise, PYLARIFY. Analysts anticipate a sequential and year-over-year decline in earnings and revenue amidst cautious sentiment on margins, despite several recent FDA approvals and a "Strong Buy" rating from most analysts. The company's full-year 2026 guidance, already below 2025 revenues, will be key to understanding its path back to growth.
Lantheus Holdings Q1 2026 Earnings Preview — May 7, Street Expects $1.23 EPS
Wall Street analysts anticipate a challenging first quarter for Lantheus Holdings, projecting earnings of $1.23 per share on $354.4 million in revenue, a significant year-over-year decline. The consensus estimates suggest a contraction of 19.6% in EPS and 4.9% in revenue compared to Q1 2025. Investors will primarily focus on margin trajectory, product pipeline updates, and management's commentary on competitive dynamics and future guidance.
Lantheus Governance Shifts And Incentives Underpin Recent Share Price Momentum
Lantheus Holdings shareholders have approved changes to their equity incentive plan, increasing available shares for grants, and will declassify the Board of Directors over three years. These governance shifts follow a period of mixed share performance for LNTH but coincide with recent positive momentum, suggesting investor approval of the changes. The article suggests these changes could better align management with shareholder interests and improve board responsiveness.
Lantheus Governance Shifts And Incentives Underpin Recent Share Price Momentum
Lantheus Holdings shareholders have approved amendments to the company's equity incentive plan, increasing the pool of shares available for grants. They also backed a proposal to declassify the Board of Directors, moving toward annual elections. These governance changes, alongside significant recent share price momentum, are expected to influence management's rewards, board responsiveness, and future decisions on capital allocation and executive pay.
Kornitzer Capital Management Inc. KS Sells 38,935 Shares of Lantheus Holdings, Inc. $LNTH
Kornitzer Capital Management Inc. KS has significantly reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 49.1%, selling 38,935 shares and retaining 40,385 shares valued at approximately $2.69 million. This adjustment comes as Lantheus reported strong fourth-quarter earnings, beating analyst expectations with $1.67 EPS and $406.8M in revenue, and issued optimistic FY2026 guidance. Analysts maintain a "Moderate Buy" rating for LNTH with a consensus target price of $88.86.
Behavioral Patterns of LNTH and Institutional Flows
This article analyzes Lantheus Holdings Inc. (NASDAQ: LNTH) using AI models, highlighting a neutral sentiment across all time horizons but anticipating a breakout. It outlines three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
Keybank National Association OH Has $2.90 Million Stock Holdings in Lantheus Holdings, Inc. $LNTH
Keybank National Association OH reduced its stake in Lantheus Holdings, Inc. by 76.7% in the fourth quarter, selling 143,395 shares and retaining 43,631 shares valued at approximately $2.90 million. Despite KeyBank's reduction, Lantheus recently exceeded earnings and revenue expectations and provided strong FY2026 guidance, maintaining a "Moderate Buy" consensus rating from analysts with significant institutional ownership. The company specializes in diagnostic imaging agents and radiopharmaceuticals for cardiovascular and oncologic diseases.
Lantheus (NASDAQ: LNTH) declassifies board and expands 2026 equity plan
Lantheus Holdings, Inc. (NASDAQ: LNTH) shareholders have approved significant governance changes, including the declassification of its Board of Directors over a three-year period and an amendment to its 2026 Equity Incentive Plan. The updated equity plan increases reserved common stock by 2,000,000 shares and sets new cash and equity compensation limits for non-employee directors. Additionally, shareholders ratified Deloitte & Touche LLP as the independent auditor for 2026 and approved executive compensation on an annual advisory basis.
Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Position in Lantheus Holdings, Inc. $LNTH
Universal Beteiligungs und Servicegesellschaft mbH significantly reduced its stake in Lantheus Holdings, Inc. by 97.1% in Q4, selling over 2.1 million shares. This comes even as Lantheus surpassed earnings and revenue expectations, reporting $1.67 EPS and $406.79 million in revenue, and issued strong FY2026 guidance. Analysts currently maintain a "Moderate Buy" consensus rating for Lantheus with an average price target of $88.86.
Vanguard Capital Management (LNTH) reports 3.42M-share stake (5.25%)
Vanguard Capital Management reported a beneficial ownership of 3,421,414 shares, or 5.25%, of Lantheus Holdings Inc. Common Stock through a Schedule 13G SEC filing. The filing indicates Vanguard possesses sole voting power for 507,100 shares and sole dispositive power for all 3,421,414 shares. This disclosure, signed on April 30, 2026, details a significant institutional stake in the company.
Sit Small Cap Growth Fund's Lantheus Holdings Inc(LNTH) Holding History
This article provides details on the Sit Small Cap Growth Fund's historical holdings of Lantheus Holdings Inc (LNTH) stock, including quarterly buy and sell data, average prices, and estimated gains. It also lists recent news articles related to Lantheus Holdings, such as upcoming earnings calls and analyst ratings with price target adjustments.
Polaris Capital Management LLC Has $35.80 Million Position in Lantheus Holdings, Inc. $LNTH
Polaris Capital Management LLC reduced its stake in Lantheus Holdings, Inc. by 15.6% in the fourth quarter, now holding 538,000 shares valued at $35.8 million, representing 3.0% of its portfolio. Despite this, Lantheus (NASDAQ:LNTH) reported strong quarterly earnings, beating consensus estimates with $1.67 EPS and $406.8 million in revenue, and set a positive FY2026 EPS guidance of 5.00-5.25. The company maintains a "Moderate Buy" consensus rating from analysts with an $88.86 price target.
